1. Fournier's Gangrene in the Course of Treatment of Advanced Hepatocellular Carcinoma with Molecular-targeted Therapy.
- Author
-
Komeda Y, Nagamatsu S, Kaya D, Sueki A, Yamamoto C, Ohta K, Matsuo Y, Nishio Y, Kikukawa S, Matsuura K, Matsuo H, Uejima M, and Moriya K
- Subjects
- Humans, Male, Aged, Molecular Targeted Therapy adverse effects, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Debridement, Carcinoma, Hepatocellular drug therapy, Carcinoma, Hepatocellular complications, Fournier Gangrene drug therapy, Fournier Gangrene chemically induced, Liver Neoplasms drug therapy, Liver Neoplasms complications, Quinolines therapeutic use, Quinolines adverse effects, Phenylurea Compounds adverse effects, Phenylurea Compounds therapeutic use
- Abstract
Lenvatinib is a molecular-targeted agent with proven efficacy against hepatocellular carcinoma (HCC). We herein report a case of lenvatinib-associated Fournier gangrene. A 66-year-old man with advanced HCC presented with a high fever 4 weeks after switching to lenvatinib. He had severe erythema in the inguinal region, and abdominal computed tomography revealed extensive emphysema and scrotal abscesses. He was diagnosed with Fournier's gangrene, and his symptoms were successfully treated with local debridement and antimicrobial therapy. Although reports of lenvatinib-associated Fournier's gangrene are rare, they should be kept in mind, as the condition could progress rapidly and have poor outcomes.
- Published
- 2025
- Full Text
- View/download PDF